Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells

被引:25
|
作者
Shida, D [1 ]
Kitayama, J [1 ]
Yamaguchi, H [1 ]
Yamashita, H [1 ]
Mori, K [1 ]
Watanabe, T [1 ]
Nagawa, H [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg Oncol, Tokyo 1138655, Japan
关键词
HER2/neu; lysophosphatidic acid; sphingosine; 1-phosphate; lysophospholipid; transactivation; receptor tyrosine kinase; gastric cancer;
D O I
10.1016/j.bbrc.2004.12.088
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ligand-less receptor HER2/neu (erbB-2) has been proposed as a prognostic marker of gastric cancer that correlates with poor clinical outcome, indicating that HER2 signals play an important role in gastric cancer progression. This study demonstrated that two Major natural lysophospholipids, lysophosphatidic acid (LPA) and sphingosine I-phosphate (SIP), induce rapid and transient phosphorylation of HER2 in two human gastric cancer cell lines, MKN28 and MKN74 cells. We also revealed that tyrosine phosphorylation of HER2 induced by both lysophospholipids was significantly attenuated by two inhibitors, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. This suggests that the pathway of HER2 transactivation induced by these lysophospholipids is dependent on the proteolytically released EGFR ligands. Our results indicate that LPA and SIP act upstream of HER2 in gastric cancer cells, and thus may act as potent stimulators of gastric cancer. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:907 / 914
页数:8
相关论文
共 50 条
  • [31] Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
    Zhang, Xiu Li
    Yang, Yun Sheng
    Xu, Dong Ping
    Qu, Jian Hui
    Guo, Ming Zhou
    Gong, Yan
    Huang, Jin
    WORLD JOURNAL OF SURGERY, 2009, 33 (10) : 2112 - 2118
  • [32] Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer
    Vaquez-martin, Alejandro
    Colomer, Ramon
    Menendez, Javier A.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (07) : 1117 - 1124
  • [33] RARE OCCURRENCE OF AMPLIFICATION OF ERBB-2(HER-2/NEU) ONCOGENE IN OVARIAN CARCINOMAS
    IMYANITOV, EN
    CHERNITSA, OI
    SEROVA, OM
    YURKOVA, LE
    VINOKUROV, VL
    KNYAZEV, PG
    EKSPERIMENTALNAYA ONKOLOGIYA, 1992, 14 (01): : 43 - 45
  • [34] HER2/C-ERBB2/NEU EXPRESSION IN NORMAL HUMAN PROLIFERATING AND DIFFERENTIAL KERATINOCYTES
    POUMAY, Y
    PITTELKOW, MR
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) : 626 - 626
  • [35] Effect of γ-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene
    Menendez, JA
    Vellon, L
    Colomer, R
    Lupu, R
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (21): : 1611 - 1615
  • [36] Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
    Reid, Alison
    Vidal, Laura
    Shaw, Heather
    de Bono, Johann
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 481 - 489
  • [37] Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu
    Roh, H
    Pippin, J
    Boswell, C
    Drebin, JA
    JOURNAL OF SURGICAL RESEARCH, 1998, 77 (01) : 85 - 90
  • [38] Expression of survivin gene (BIRC5) and ErbB-2 (Her-2/neu) in lymphocytes in breast cancer
    Shlyakhtunou, Y.
    Semenov, V.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S105 - S105
  • [39] The HER2/neu (erbB2) polymorphism, body mass index, and the risk of endometrial cancer
    Lee, J.
    Tong, S.
    Lee, K.
    Kim, J.
    Kwon, Y.
    Kim, J.
    Kim, Y.
    Yei, J.
    Do, Y.
    Kwon, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu):: A study of incidence and correlation with outcome in breast cancer
    Thor, AD
    Liu, S
    Edgerton, S
    Moore, D
    Kasowitz, KM
    Benz, CC
    Stern, DF
    DiGiovanna, MP
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) : 3230 - 3239